cell-mediated inflammatory process, which plays an important role in the pathogenesis of cancer. In this study, we examined whether genetic polymorphisms in IL-23R are associated with cancer risk in 4936 cancer patients and 5664 control subjects from eastern and southern Chinese populations. We found that the C allele of the rs10889677A>C polymorphism in the 3′-untranslated region of IL-23R was inversely associated with risk of multiple types of cancer, including breast cancer, lung cancer and nasopharyngeal carcinoma. Healthy controls who harbored the rs10889677C allele had significantly decreased cancer risk (odds ratio = 0.74, 95% confidence interval = 0.71-0.78) compared with those who harbored the rs10889677A allele. Biochemical analysis demonstrated that the rs10889677A allele disrupted the binding site for the micro-RNA miR-let-7f, thereby increasing the transcription of the IL-23R in vitro and in vivo. Furthermore, cancer-free individuals carrying the rs10889677CC homozygous genotype had a lower proportion of regulatory T cells (Tregs) and a higher T-cell proliferation rate upon stimulation with concanavalin A than individuals carrying the rs10889677AA homozygous genotype. Our findings indicate that the IL-23R rs10889677A>C polymorphism may influence T-cell proliferation, resulting in changes in the levels of Tregs in vivo and modifying cancer susceptibility.
Introduction
The interleukin-23 receptor (IL-23R) is composed of IL-23R and IL-12Rβ1 subunits, which is shared with IL-12R (1). IL-23/IL-23R is essential for the T-helper 17 (Th17) cell-mediated immune response (2, 3) . Th17 cells are a recently discovered proinflammatory CD4 + effector T-cell population that contributes to pathogen clearance and tissue inflammation by expressing high levels of the proinflammatory cytokine IL-17 in response to stimulation (4) . Recently, the novel inflammation pathway axis IL-23→IL-23R→STAT3→Th17→IL-17/ IL-17F (IL-23/IL-17 axis) has been shown to play a pivotal role in inflammatory and autoimmune diseases (5) . IL-23R plays an important role in the initiating, maintaining and accelerating the IL-23/ IL-17 inflammatory signal transduction pathway (6) .
Studies on the roles of IL-17, IL-23, IL-23R and Th17 cells in cancer have produced largely contradictory or controversial results.
However, IL-17 expression in tumors has been correlated with increased tumor microvascular density, tumor differentiation and a generally unfavorable prognosis (7) . Moreover, previous studies have indicated that IL-23R can promote tumor growth and may decrease immunosurveillance by CD8 + T cells (8) . IL-23R signaling in regulatory T cells (Tregs) may also promote the immunosuppressive function of Tregs in the tumor microenvironment, facilitating evasion of the immune system by the tumor (9) (10) (11) . Interestingly, both Th17 cells and Tregs can promote tumor growth, and evidence suggests that there may be an association between these two T-cell subtypes (12) . These findings suggest that IL-23R may play an important role in cancer development and progression.
IL-23R is encoded by the IL-23R gene, which maps within 151 kb of the IL12RB2 gene on chromosome 1 (1p31.2~32.1). Several lines of evidence suggest that cellular immune surveillance play a pivotal role in the development of cancer, including breast cancer, lung cancer and nasopharyngeal carcinoma (13) (14) (15) (16) . Previous studies have reported that single nucleotide polymorphisms (SNPs) in IL-23R may be associated with the risk of gastric and esophageal cancer (17) (18) (19) ; however, the association between the SNPs in IL-23R and risk for breast cancer, lung cancer and nasopharyngeal carcinoma in Chinese population remains unclear, and biological functions of these SNPs have not yet been elucidated. We hypothesized that IL-23R SNPs enhance the IL-23/IL-17 pathway and may play a role in human cancer development. To test this hypothesis, we investigated the association between various IL-23R genotypes and the risk for the development of multiple types of cancer in two Chinese populations.
Materials and methods

Study subjects
Overall, all subjects in this study were unrelated Han Chinese from eastern or southern Chinese populations. There were no age, stage and histology restriction for cancer patients. Patients or controls who recently (in last 6 months) had blood transfusions were excluded. All healthy controls had no documented history of cancer and were frequency matched to each set of cancer patients based on their age (±5 years), sex and residential area (urban or rural). In the family history section of the interview, all subjects, self and surrogate respondents, were first asked the number of brothers and sisters they had. Subjects were then asked whether there was a history of all malignant tumors in the immediate family, which included fathers, mothers, brothers and sisters. The control subjects for breast cancer patients were all female. The tumor-node-metastasis classification and tumor staging were evaluated according to the 2002 American Joint Committee on Cancer staging system. Study subjects' demographics are summarized in Supplementary Tables 1-3,  available at Carcinogenesis Online. In the eastern Chinese population, patients with breast cancer (n = 1010), lung cancer (n = 503) and nasopharyngeal carcinoma (n = 684) were recruited from the First Affiliate Hospital of Soochow University (Suzhou) between March 2001 and May 2009 with a response rate of 89%. We selected these cancer sites because the samples were available to us from previous studies in our laboratory (20) (21) (22) . The eastern Chinese healthy controls (n = 2701) were randomly selected from a database of 3500 individuals who underwent a hospital-based physical examination annually (regular check-up/preventive care) in the Suzhou city during the same time period, in which the cancer patients' blood samples were collected, with a response rate of 90%. In the southern Chinese population, patients with breast cancer (n = 804), lung cancer (n = 1056) and nasopharyngeal carcinoma (n = 906) were recruited from the Tumor Hospitals affiliated with Guangzhou Medical University between 2002 and 2009 with a response rate of 91%.The southern Chinese healthy controls (n = 2963) were randomly selected from a pool of 5000 individuals who also participated in a hospital-based screening program for health check-ups conducted in the Guangdong province during the same time period, in which cancer patients' blood samples were collected, with a response rate of 92%.
Our study included two independent case-control data sets (Supplementary Figure 1 , available at Carcinogenesis Online) that were described previously (20, 21) . The discovery set included 1010 breast cancer patients and 1014 sex, age and residential area (urban or rural) matched healthy controls from the eastern Chinese population (Supplementary Table 1 , available at Carcinogenesis Online). The validation set included patients with lung cancer (n = 503), nasopharyngeal carcinoma (n = 684) and 1687 sex, age and residential area (urban or rural) matched healthy controls from the eastern Chinese population, as well as patients with breast cancer (n = 804), lung cancer (n = 1056), nasopharyngeal carcinoma (n = 906) and 2963 sex, age and residential area (urban or rural) matched healthy controls from the southern Chinese population (Supplementary Tables 1-3, available at Carcinogenesis  Online) .
For functional assays, sufficient blood samples were obtained from 37 healthy volunteers (20 males and 17 females) between the ages of 19 and 49 years, who were employed at our institution. The 37 healthy controls were randomly selected from volunteers including 186 healthy individuals as determined by physical examination. At the time of recruitment for the study, informed consent was obtained from each subject, and this study was approved by both the medical ethics committee of Soochow University and the institutional review boards of Guangzhou Medical University. 
SNP selection
Genotyping analysis
Genomic DNA was isolated from peripheral blood lymphocytes of all the study subjects. All subjects were genotyped for the rs6682925, rs6683039, rs1884444 and rs10889677 SNPs by using the allele-specific matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (Sequenom, SanDiego, CA) (21) . A total of 80 samples were randomly selected for direct sequencing to confirm the genotyping results from the mass spectrometric analysis, and the results were in 100% agreement. Approximately, 10% of the samples were also randomly selected for a blinded repeat of the genotyping without prior knowledge of the previous genotyping result or the status of being a case and control, and the results were in 100% agreement.
IL-23R 3′UTR luciferase constructs generation
The 3′UTR of Renilla luciferase in the vector psiCHECK-2 (Promega, Madison, WI) was replaced with the full-length 3′UTR of the IL-23R gene containing either the rs10889677C or rs10889677A allele. The resulting constructs (psiCHECK-2-IL-23R-3′UTR-A-allele and psiCHECK-2-IL-23R-3′UTR-C-allele) were verified by sequencing (see Supplementary Materials and methods, available at Carcinogenesis Online).
Transient transfections and luciferase assays
The 293T or Jurkat cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. After transfection for 24 h, the luciferase activity was measured with the Dual-Luciferase Reporter assay system (Promega, Madison, WI) (see Supplementary Materials and methods, available at Carcinogenesis Online).
Real-time PCR analysis of IL-23R messenger RNA and miR-let-7f
The relative gene expression for the IL-23R gene was quantified using the ABI Prism 7000 sequence detection system (Applied Biosystems) based on the SYBR-Green method. The TaqMan MicroRNA Assays (Applied Biosystems) was used to detect miR-let-7f expression according to the manufacturers' protocol (see Supplementary Materials and methods, available at Carcinogenesis Online). All analyses were performed in a blinded fashion in which the laboratory personnel were unaware of the genotyping data.
Flow cytometry analysis
A flow cytometer (FACScalibur; BD Biosciences) was used to measure the cell surface expression of IL-23R, CD39, CD8 and CD4 as well as the intracellular expression of FOXP3 (see Supplementary Materials and methods, available at Carcinogenesis Online). Data were analyzed with CELLQUEST (BD Immunocytometry Systems) and FlowJo (Tree Star, Ashland, OR) software.
Peripheral blood mononuclear cell isolation and in vitro sensitization
Peripheral blood mononuclear cells (PBMCs) (1 × 10 6 cells/ml) were isolated by Ficoll-Paque (Amersham Pharmacia Biotech) density-gradient centrifugation and were suspended in RPMI-1640 supplemented with 1% Nutridoma SP (Boehringer Mannheim) and 1% fetal bovine serum. PBMCs were dispensed into culture wells, and the cells were stimulated with concanavalin A (ConA; Sigma-Aldrich) at a final concentration of 10 mg/l.
CFDA-SE labeling of PBMCs
The diacetate form of CFDA-SE is a nontoxic, nonfluorescent molecule that can positively diffuse into cells and, once inside the cells, forms CFSE, which emits light with characteristic wavelengths, producing a homogeneous labeling of cell populations. CFDA-SE was used to assess lymphocyte proliferation as originally described by Lyons and Parish (24) . The population-specific proliferation of CD4-and CD8-positive T cells was also assessed by staining with both cell surface marker after CFDA-SE labeling. PBMCs (1 × 10 6 ) were incubated with 2 µl CFDA-SE according to the manufacturer's suggested protocol (Molecular Probes, Eugene, OR) and were cultured for 24 h in the presence of the mitogen ConA (as described in PBMC isolation and in vitro sensitization).
Measurement of [3H]-thymidine incorporation
PBMCs (1 × 10 6 cells/ml) from 37 subjects were cultured in RPMI-1640 supplemented with 1% Nutridoma SP (Boehringer Mannheim) and 1% fetal bovine serum. The samples were analyzed in triplicate in final volumes of 100 µl in 96-well plates. The cells were treated with ConA (0.3-40 µg/ml). To evaluate DNA synthesis, 0.5 µCi [
3 H]-thymidine (6.7 Ci/mmol; ICN; 1 Ci = 37 GBq) was added to each well, and after 8 h, the cells were harvested onto glassfiber filters with a PHD cell harvester (Cambridge Technology, Watertown, MA). The filters were air dried, and radioactivity was measured by liquid scintillation spectroscopy on a Betaplate scintillation counter (LKB).
Enzyme-linked immunosorbent assay
A total of 41 serum samples were randomly selected from a serum database including 237 healthy individuals as determined by physical examination. The serum levels of IL-17 and IL-10 were measured with an enzyme-linked immunosorbent assay kit specifically designed (BioLegend, San Diego, CA) for the detection of IL-17 and IL-10 protein levels according to the manufacturer's instructions. All analyses were performed in a blinded fashion in which the laboratory personnel were unaware of the genotyping data.
Statistical analysis
Chi-squared tests were used to assess the differences in the age and sex distributions of the cases and controls as well as differences in the various polymorphisms and the presence of disease. The Hardy-Weinberg Equilibrium (HWE) was tested with a goodness-of-fit chi-squared test to compare the expected genotype frequencies with the observed genotype frequencies (p 2 + 2pq + q 2 = 1) in the cancer-free controls. Because we frequency matched the case and control on sex and age, only the unconditional logistic regression model was used to estimate the association between the SNPs and cancer risk. The cancer risk associated each SNP was measured by odds ratio (OR) and its corresponding 95% confidence interval (CI) by using an unconditional logistic regression model with adjustments for age, gender, smoking status, drinking status, body mass index (BMI) and family history of all malignant tumors as appropriate. We analyzed the number of variant (i.e. n = 0 for AA; n = 1 for AC; n = 2 for CC) in logistic regression; the P value for the number of variant is the trend test's P value, and it was trend test for rare variant. Data were further stratified to evaluate the stratum-specific ORs among the IL-23R rs10889677A>C genotypes, which were further tested for homogeneity within the strata. The falsepositive report probability (FPRP) test was applied to detect the probability of false-positive association findings (25) . Student's t-test was used to compare the differences in the levels of luciferase reporter gene expression. One-way analysis of variance (ANOVA) tests and linear regression models with adjustments for age, gender, smoking status, drinking status, BMI and family history of all malignant tumors were used to evaluate the effect of various SNPs on the IL-23R messenger RNA (mRNA) and protein expression levels in PBMCs as well as the T-cell proliferation rates and Treg levels in 37 healthy control subjects. All tests were two sided and were performed with the SAS software (version 9.1; SAS Institute, Cary, NC, USA). A P value < 0.05 was considered statistically significant.
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Results
Identification of IL-23R SNPs associated with cancer susceptibility
Four candidate SNPs of the IL-23R gene were genotyped in a discovery set consisting of 1010 breast cancer patients and 1014 cancer-free controls from the eastern Chinese population (Table I) . A significant association with breast cancer risk was observed for the rs10889677 SNP, but the other SNPs, rs6682925, rs6683039 and rs1884444, were not significantly associated with the risk of breast cancer (Table  I) . Genotype distributions of all SNPs were found to be consistent with HWE. We also performed a linkage disequilibrium analysis of the control samples and found that the rs10889677 locus was not in high linkage disequilibrium with the other three SNPs (compared with rs1884444, D′ = 0.023 and r 2 = 0.01; compared with rs6683039, D′ = 0.206 and r 2 = 0.026; compared with rs6682925, D′ = 0.186 and r 2 = 0.023); however, the rs6683039 locus was in high linkage disequilibrium with the other two SNPs (compared with rs6682925, D′ = 1 and r 2 = 0.987; compared with rs1884444, D′ = 1 and r 2 = 0.726). From the analysis of the validation set, the rs10889677 SNP was selected for further analysis of the association with a decreased risk for breast, lung and nasopharyngeal cancer (Table II) . The genotype distributions of all SNPs in these analyses also agreed with HWE (P > 0.05). In the eastern Chinese population, the ORs associated with the IL-23R rs10889677AC or rs10889677CC genotype were 0.70 Table I Tests for trend of odds were two sided and were based on likelihood ratio tests assuming a multiplicative model. Tests for trend of odds were two sided and based on likelihood ratio tests assuming a multiplicative model.
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(95% CI 0.52-0.95) to 0.85 (95% CI 0.69-1.01) or 0.44 (95% CI 0.31-0.63) to 0.64 (95% CI 0.44-0.93), respectively, when compared with the IL-23R rs10889677AA genotype. These associations were confirmed in the southern Chinese population, in which the ORs associated with the IL-23R rs10889677CC genotype for risk of breast cancer, lung cancer and nasopharyngeal carcinoma patient groups were 0.44 (95% CI 0.31-0.63), 0.49 (95% CI 0.34-0.69) and 0.55 (95% CI, 0.38-0.79), respectively, when compared with the IL-23R rs10889677 AA genotype. After adjusting for age, sex, smoking status, drinking status, BMI and family history of all malignant tumors, there were no significant changes in the respective ORs. FPRP analysis was also performed and revealed that, assuming a prior probability of 0.001 and a prior OR of 0.67, as suggested by Wacholder et al. (25) , the FPRP for the observed association between the IL-23R rs10889677C allele and the risk for all cancers yielded a value of 0.09, which was lower than the pre-set FPRP level of 0.20.
Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry was used to genotype for rs6682925, rs6683039 and rs1884444 polymorphisms in breast, lung and nasopharyngeal cancer patients and healthy controls from eastern and southern Chinese population. However, no significant association was observed between these polymorphisms and the risk of these cancers in either population or in their combination, as shown in Supplementary Table 4, available at Carcinogenesis Online.
IL-23R rs10889677A>C genotypes affect IL-23R expression by inhibiting the binding of miR-let-7f in vitro
According to two bioinformatics analysis software programs (MIRanda Java Interface v1.0 and http://snpinfo.niehs.nih.gov/snpfunc.htm), the IL-23R rs10889677A>C polymorphism lies within a predicted binding site for human miR-let-7f. Therefore, we hypothesized that miRlet-7f would bind tightly to IL-23R mRNA transcripts containing the rs10889677C allele, resulting in the downregulation of IL-23R expression. Conversely, the binding of miR-let-7f to mRNA transcripts containing the rs10889677A allele would be disrupted, resulting in the upregulation of IL-23R expression. To test this hypothesis, the human embryonic kidney cell line 293T was transiently co-transfected with miR-let-7f and either of the polymorphic reporter constructs and assessed for the luciferase activity. Compared with the construct containing the rs10889677A allele, the construct containing the rs10889677C allele exhibited significantly reduced luciferase activity in a concentrationdependent manner ( Figure 1A) . The same experiments were repeated using Jurkat cells, which generated similar results ( Figure 1B) .
Jurkat cells and 293T cells were also co-transfected with the psiCHECK-2-IL-23R-3′UTR vector, 40 pmol miR-let-7f and the miR-let-7f inhibitor. The miR-let-7f inhibitor is a single-stranded antisense RNA molecule that complements and knocks down endogenous miR-let-7f. In both cell lines, no significant differences in luciferase activity were observed in the presence of the micro RNA-let-7f inhibitor ( Figure 1C) . These results suggest that miRlet-7f negatively may regulate the transcription of IL-23R and that miR-let-7f regulation may be inhibited by the presence of the rs10889677C allele.
Association of IL-23R rs10889677A>C genotypes with IL-23R expression
To further explore the effects of IL-23R rs10889677A>C on the transcription of the IL-23R gene, we used PBMCs from 37 cancer-free controls (6 rs10889677CC, 19 rs10889677AC and 12 rs10889677AA). The effect of the rs10889677A>C SNP on the IL-23R mRNA expression was quantified by real-time PCR. Subjects with the rs10889677AA genotype expressed significantly higher IL-23R mRNA levels (0.29 ± 0.07) than those with the rs10889677AC (0.10 ± 0.03) or rs10889677CC genotypes (0.08 ± 0.04; ANOVA test: P = 0.007; linear regression test: P = 0.004, Figure 1D ). To determine whether miR-let-7f is constitutively expressed in PBMCs, quantitative real-time PCR was used to examine miR-let-7f expression. miR-let-7f was constitutively expressed in PBMCs; however, there was no significant association between the background expression of miR-let-7f and the IL-23R rs10889677A>C genotypes in PBMCs collected from cancer-free individuals (0.346 ± 0.074 for AA; 0.322 ± 0.049 for AC and 0.298 ± 0.068 for CC; ANOVA test: P = 0.836; linear regression test: P = 0.562, Supplementary Figure 2B , available at Carcinogenesis Online). 
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The expression level of IL-23R in PBMCs from healthy individuals was assessed by flow cytometry. The percentage of CD4 + T cells expressing IL-23R in PBMCs from healthy individuals with the rs10889677AA genotype (0.89 ± 0.07%) was significantly higher than the percentage of CD4 + T cells from healthy individuals with the rs10889677AC (0.68 ± 0.05%) or rs10889677CC genotypes (0.51 ± 0.06%; ANOVA test: P = 0.0025; linear regression test: P = 0.0018). CD4 + T cells from subjects with the rs10889677AA genotype (708.43 ± 37.19) also had a higher IL-23R mean fluorescence intensity than CD4 + T cells from subjects with the rs10889677AC (632.42 ± 43.59) or rs10889677CC genotypes (513.91 ± 40.56; ANOVA test: P = 0.0189; linear regression test: P = 0.0075, Figure 2A) . Similarly, the percentage of CD8 + T cells expressing IL-23R in PBMCs from healthy individuals with the rs10889677AA genotype (1.08 ± 0.14%) was higher than in PBMCs from healthy individuals with the rs10889677AC (0.78 ± 0.07%) or rs10889677CC genotypes (0.58 ± 0.07%; ANOVA test: P = 0.0015; linear regression test: P = 0.0034). CD8 + T cells from subjects with the rs10889677AA genotype also had a higher IL-23R mean fluorescence intensity (680.33 ± 94.47) than those from healthy individuals with the rs10889677AC (610.72 ± 30.40) or rs10889677CC genotypes (452.91 ± 30.15; ANOVA test: P = 0.0027; linear regression test: P = 0.0043, Figure 2B ).
Effects of the IL-23R rs10889677A>C genotypes on T-cell proliferation
We next sought to elucidate whether the different IL-23R rs10889677A>C genotypes affect the T-cell proliferation rate in vitro. The median percentage of CD4 + cells in PBMCs from healthy individuals expressing the IL-23R rs10889677AA genotype (19.61 ± 1.59%) was significantly lower than that in PBMCs from healthy individuals expressing the rs10889677AC (26.87 ± 1.26%) or rs10889677CC genotypes (33.03 ± 2.14%; ANOVA test: P < 0.0001; linear regression test: P < 0.0001; Figure 3A) . Similarly, the median percentage of CD8 + cells in PBMCs from healthy individuals expressing the IL-23R rs10889677AA genotype (15.19 ± 1.64%) was also significantly lower than that in healthy individuals expressing the rs10889677AC (22.86 ± 0.71%) or rs10889677CC genotypes (27.15 ± 2.25%; ANOVA test: P < 0.0001; linear regression test: P < 0.0001, Figure 3B ). In addition, [
3 H]-thymidine incorporation assays were performed to detect T-cell proliferation after stimulation with ConA. PBMCs from healthy individuals expressing the IL-23R rs10889677AA genotype (1.34 ± 0.10) exhibited a significantly lower proliferation rate than PBMCs from healthy individuals expressing the rs10889677AC (1.56 ± 0.12) or rs10889677CC genotypes (3.31 ± 0.58; ANOVA test: P = 0.0002; linear regression test: P = 0.0003, Figure 4A )
Effects of the IL-23R rs10889677A>C genotypes on the proportion of Tregs in vivo
Because IL-23R signaling in Tregs promotes an immunosuppressive phenotype, which further promotes carcinogenesis, we investigated whether the rs10889677A>C polymorphism affects the Treg population in vivo. PBMCs from healthy individuals harboring the rs10889677AA genotype (1.91 ± 0.28%) had a higher proportion of CD4 + FOXP3 + T cells than PBMCs from healthy individuals harboring the rs10889677AC (1.07 ± 0.13%) or rs10889677CC genotypes (0.91 ± 0.10%; ANOVA test: P = 0.0017; linear regression test: P = 0.0005, Figure 3C ). Furthermore, PBMCs from healthy individuals harboring the rs10889677AA genotype (4.03 ± 0.94%) had a higher percentage of CD4 + CD39 + T cells than PBMCs from healthy individuals harboring the rs10889677AC (1.34 ± 0.36%) or rs10889677CC genotypes (1.01 ± 0.37%; ANOVA test: P = 0.0021; linear regression test: P = 0.0032, Figure 3D ).
Serum levels of IL-17 and IL-10 in healthy controls with different IL-23R rs10889677A>C genotypes
The IL-23R signaling may trigger the development of the Th17 population and promote the immunosuppressive function of Tregs, thus leading to specific changes in the expression of the downstream cytokines IL-17 and IL-10 (26). Therefore, we assessed IL-17 and IL-10 protein levels in serum samples from 41 cancer-free controls according to the different rs10889677A>C genotypes (6 rs10889677CC, 17 rs10889677AC and 18 rs10889677AA). Our result revealed that subjects with the rs10889677AA genotype had significantly higher IL-17 levels (mean ± standard error of the mean, 29.285 ± 0.557 pg/ml) than those with the rs10889677AC (25.453 ± 0.631 pg/ml) or rs10889677CC genotypes (22.117 ± 1.007 pg/ml; ANOVA test: P < 0.001; linear regression test: P < 0.001), as shown in Figure 4B . Similarly, healthy individuals with the rs10889677AA (19.757 ± 0.486 pg/ml) genotype exhibited higher IL-10 levels than those with the rs10889677AC (16.189 ± 0.531 pg/ml) or rs10889677CC genotypes (13.967 ± 0.802 pg/ml; ANOVA test: P < 0.001; linear regression test: P < 0.001; Figure 4C ). 
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Stratified analysis of the IL-23R rs10889677A>C genotypes and the associated risk for several cancers
A stratified analysis assessing the associations between the IL-23R rs10889677A>C genotypes and the risk of various cancers was conducted. However, no significant association was found between the various rs10889677A>C genotypes and breast, lung and nasopharyngeal cancer risks (Supplementary Figure 3 , available at Carcinogenesis Online)
Discussion
The IL-17/IL-23 inflammation pathway plays an important role in the regulation of cancer development and tumor immunity, but the mechanisms involved are poorly understood. Elucidating the role of IL-17/ IL-23 and Th17 cells may aid in understanding the regulation of the inflammation response in tumor development and may provide novel ways of modulating the cancer microenvironment in patients. In this study, we have shown that the risks of breast, lung and nasopharyngeal cancer are inversely associated with the rs10889677C allele, which itself alters miR-let-7f-mediated IL-23R expression. In addition, the IL-23R rs10889677A allele was correlated with an increase in the proportion of Tregs in vivo and a lower T-cells proliferation rate in vitro relative to the IL-23R rs10889677C allele. The association between this polymorphism and several cancers with diverse etiologies raises the possibility that IL-23R variant might be a common susceptibility factor for human cancer.
The importance of IL-23R in tumor development and its influence on tumor immunity has been well recognized (7) . Therefore, it is biologically reasonable that functional IL-23R polymorphisms may play a role in the development of cancer. In fact, studies have shown that IL-23R polymorphisms are associated with susceptibility to gastric cancer (19) . In a previous study of gastric cancer, which included 941 cancer patients and 775 Chinese (Guangzhou) control subjects, Chen et al. (17) found that the rs10889677CC genotype was associated with a significantly reduced risk of gastric cancer, compared with the more common rs10889677AA genotype. Two other independent studies of Chinese populations have shown that the rs10889677C allele may increase the risk of oral cancer (27) and ovarian cancer (28), compared with the rs10889677A allele. Nevertheless, these two studies had a relatively small number of study subjects (240 oral cancer patients and 240 Taiwanese control subjects; 96 ovarian cancer patients and 115 Chinese control subjects), which did not have adequate statistical power to draw strong conclusions (20.2% and 14.4%, respectively). Our study achieved a >99.0% statistical power (two-sided test, α = 0.05) to detect an OR of 0.74 for the rs10889677C variant allele (which occurred at a frequency of 0.330 in the controls). The FPRP for the observed association between the IL-23R rs10889677C allele and the risk for all cancers yielded a value of 0.09, which was lower than the pre-set FPRP level of 0.20, suggesting that this finding is noteworthy. Recently, several genome-wide association studies (GWAS) have reported several novel SNPs (rs2046210, rs11249433, rs2981582, rs3817198, rs889312 and so on) that are associated with the development of breast cancer (29) (30) (31) (32) (33) (34) (35) ; however, most of the studies were based on Caucasians (29) (30) (31) (32) (33) 35) and only one GWAS was based on Chinese (34) . A GWAS of nasopharyngeal carcinoma also reported three susceptibility loci in Chinese population, including rs9510787, rs6774494 and rs1412829 (36) . Interestingly, candidate genes of these loci may relate to the immune response (37) (38) (39) . The IL-23R gene, which maps to chromosome 1 (1p31.2~32.1), GWAS have reported that chromosomal loci from 1p31 to 1p36 were strongly associated with the development of cancers in Asian populations (40, 41) . Kiyotani et al. (40) identified locus at 1p31 associated with clinical outcomes of breast cancer patients with tamoxifen treatment in Japanese, and our previous GWAS data in Chinese populations have also indicated that these loci may be associated with lung cancer risk (42) . Due to the limitation of SNP coverage in the Affymetrix Genome-Wide SNP Array 6.0 chip, previous GWAS regarding cancer in Chinese patients do not include these SNPs (34, 42, 43) ; therefore, the association between IL-23R rs10889677A>C polymorphism and the risk for cancer in Chinese population remains unclear, and casecontrol studies with large sample sizes and different cancer types are needed.
Evidence for the biological function of the IL-23R rs10889677A>C SNP has been limited in previous studies. (45) . IL-23R signaling in Tregs promotes an immunosuppressive phenotype in the tumor environment (46) , which promotes carcinogenesis. Tumor-associated Tregs express the IL-23R, which activates Stat3, resulting in the upregulation of the immunosuppressive cytokine IL-10. Our functional results are consistent with previous findings on the contributions of miR-let-7f and IL-23R to the immune response. Furthermore, T-cells proliferation experiments indicated that a subtle change in IL-23R function due to variations in the rs10889677A>C polymorphism may interfere with T-cell proliferation. Because T lymphocytes play an important role in the immune surveillance of cancer cells (47, 48) , individuals who carry the IL-23R rs10889677A allele and thus have lower rates of T-cell proliferation would be predicted to have a higher risk for developing breast, lung and nasopharyngeal cancers.
Our results regarding associations between the IL-23R rs10889677A>C polymorphism and susceptibility to cancer were obtained from multiple independent case-control analyses derived from eastern and southern Han Chinese populations, and genotyping of the samples was performed in two independent laboratories. The relatively large sample sizes decreased the size of ORs that can be detected statistically, due to increased power. The genotype frequencies of all the SNPs in the controls were aligned with HWE and were identical in the two populations, further supporting the random nature of our method for selecting controls. Moreover, the associations between the SNPs and cancer risks observed in our study are biologically plausible because they are consistent with our functional findings. Nevertheless, further studies of breast, lung and nasopharyngeal cancers as well as other cancers would be beneficial to confirm our results.
In conclusion, our study demonstrated an association between the IL-23R rs10889677C allele and reduced risk of breast, lung and nasopharyngeal cancers. The rs10889677C allele resides in the 3′UTR of the IL-23R gene and results in the inhibition of the interaction with Th17 and Treg cells, which consequentially increases the proliferation rate of T lymphocytes and may explain the observed decrease in cancer susceptibility. Together with previous studies (49, 50) , our results further support the hypothesis that genetic polymorphisms that influence the efficacy of the immune system may modify cancer susceptibility.
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